KERREY J ROBERT sold $3.2M of THC

KERREY J ROBERT sold 12,010 shares of TENET HEALTHCARE CORP (THC) at an average of $263.72 ($263.04–$264.62, $3.17M total) across 3 trades on 2026-09-14.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published Sep 17, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 12:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

The director's divestiture may be interpreted as a negative signal, but the modest remaining stake limits impact.

02

Market read

Primary relevance to THC shareholders; minimal spillover to broader market.

03

What to watch

No disclosed reason for the sale; could be personal liquidity needs rather than lack of confidence.

Relevance 6/10Novelty 5/10Timing: post‑filing 2026‑09‑16

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

Director Kerrey J. Robert sold 12,010 shares for $3.17M, reducing his stake to 4,794 shares.

Expected impact

Modest downside pressure; price could dip 1‑2% in the next trading session.

Evidence & confidence

A $3.2M sale by a director is material but not unusually large for Tenet; market may view it as a neutral to slightly bearish signal.

Market effects

Healthcare services sector may see slight scrutiny of insider activity but no broad impact.

U.S. market; limited regional effect.

Low; relevance confined to Tenet Healthcare investors.

Counterpoint

The sale could be a routine portfolio rebalancing unrelated to company outlook.

Key entities

  • Tenet Healthcare Corp

    U.S. healthcare services provider (ticker THC).

  • Kerrey J. Robert

    Director of Tenet Healthcare who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.